---
document_datetime: 2023-09-21 19:21:05
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/fabrazyme-epar-all-authorised-presentations_en.pdf
document_name: fabrazyme-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 1.080522
conversion_datetime: 2025-12-26 13:15:33.641764
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| EU Number       | Invented name   | Strength   | Pharmaceutical form                              | Route of administration   | Packaging    | Package size   |
|-----------------|-----------------|------------|--------------------------------------------------|---------------------------|--------------|----------------|
| EU/1/01/188/001 | Fabrazyme       | 35 mg      | Powder for concentrate for solution for infusion | Intravenous use           | Vial (glass) | 1 vial         |
| EU/1/01/188/002 | Fabrazyme       | 35 mg      | Powder for concentrate for solution for infusion | Intravenous use           | Vial (glass) | 5 vials        |
| EU/1/01/188/003 | Fabrazyme       | 35 mg      | Powder for concentrate for solution for infusion | Intravenous use           | Vial (glass) | 10 vials       |
| EU/1/01/188/004 | Fabrazyme       | 5 mg       | Powder for concentrate for solution for infusion | Intravenous use           | Vial (glass) | 1 vial         |
| EU/1/01/188/005 | Fabrazyme       | 5 mg       | Powder for concentrate for solution for infusion | Intravenous use           | Vial (glass) | 5 vials        |
| EU/1/01/188/006 | Fabrazyme       | 5 mg       | Powder for concentrate for solution for infusion | Intravenous use           | Vial (glass) | 10 vials       |